Pharma Report on Aryl Hydrocarbon Receptor – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/aryl-hydrocarbon-receptor-pipeline-review-h2-2020-645868.html

Aryl Hydrocarbon Receptor – Pipeline Review, H2 2020

Summary

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Aryl Hydrocarbon Receptor – Pipeline Review, H2 2020, outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 2, 13 and 4 respectively.Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Infectious Disease, Metabolic Disorders, Ophthalmology, Genetic Disorders and Respiratory which include indications Coronavirus Disease 2019 (COVID-19), Psoriasis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Atopic Dermatitis (Atopic Eczema), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Multiple Sclerosis, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Uveitis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), Alopecia, Androgen-Sensitive Prostate Cancer, Blepharitis, Burkitt Lymphoma, Celiac Disease, Crohn’s Disease (Regional Enteritis), Dengue Fever, Globoid Cell Leukodystrophy (Krabbe Disease), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hematopoietic Stem Cell Transplantation, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Mantle Cell Lymphoma, Melanoma, Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Multiple Myeloma (Kahler Disease), Myasthenia Gravis, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Oral Cancer, Osteoarthritis Pain, Pancreatic Ductal Adenocarcinoma, Pemphigus, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Vitiligo, Wet (Neovascular / Exudative) Macular Degeneration and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
– The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects
– The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics

Reasons to Buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned:
Actavalon Inc
Active Biotech AB
Ampio Pharmaceuticals Inc
AnTolRx Inc
Bayer AG
Dermavant Sciences Inc
Hercules Pharmaceuticals BV
Hutchison MediPharma Ltd
Ikena Oncology Inc
JAGUAHR Therapeutics Pte Ltd
Magenta Therapeutics Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Shenogen Pharma Group Ltd
Sol-Gel Technologies Ltd
Welichem Biotech Inc


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645868

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.